IMAGING THROMBOEMBOLISM WITH TC-99M-PEPTIDE, TP1201

描述：调查人员提议测试 开发血栓栓塞症的核医学成像方法 ~(99m)Tm标记的血栓反应蛋白CSVTCG多肽片段， 两者都与主要的血小板糖蛋白CD36结合，并进一步 由他们的摘要描述的： 有近50万起事件和20万人死于深渊 美国每年的静脉血栓形成(DVT)和肺栓塞(PE)， 以及他们神秘的、非侵入性的诊断评估，需要 能迅速、可靠地检测出DVT或PE的TC-99M试剂更可怕 比以往任何时候都要好。而大量放射性标记的单抗 抗体，其中大多数是针对血小板表面糖蛋白IIb的- IIIA建筑群已经被调查过了，原因多种多样，目前还没有人 为这些患者的管理做出了重大贡献。 与三种多肽不同的是，抗血小板因子IV、DMP 444和 蛇毒因子，作为检测PE和DVT的试剂进行研究， 所讨论的多肽CSVTCG是一种自然存在于 最内源性蛋白的分子结构域，凝血酶敏感蛋白，它 通过激活的血小板在DVT的形成中发挥积极作用。 此外，与其他三种多肽不同，CSVTCG与主要的血小板结合 糖蛋白CD36(GPIV，GPV)。 我们成功地用~(99)T标记了CSVTCG，并对其生物学特性进行了检测。 活性，并确定其选择性结合激活的能力 通过GP CD 36检测血小板。我们对~(99m)Tc-CSVTCG(~(99)m-TP-1201)进行了评价 标记体外形成和预制的血液凝块，并检测 体内实验性深静脉血栓形成。结果是非常令人鼓舞的， 已经产生了促使我们进行这项工作的动力 系统的可行性研究，将确定其作为代理人的潜力 用于DVT和PE的闪烁成像。 建议的商业应用：不可用

DESCRIPTION: The investigators propose to test the feasibility of developing a method for nuclear medical imaging of thromboembolism with a technetium-99m-labeled CSVTCG peptide fragment of thrombospondin protein, both of which bind to the major platelet glycoprotein, CD36, as further described by their abstract: "With nearly half a million incidences and 200,000 deaths due to deep venous thrombosis (DVT) and pulmonary embolism (PE) in the USA each year, and their enigmatic, non-invasive diagnostic assessment, the need for a Tc-99m agent that can detect DVT or PE promptly and reliably is more dire than ever before. While a large number of radiolabeled monoclonal antibodies, most of them specific for platelet surface glycoprotein IIb- IIIa complex have been investigated, for a variety of reasons none has yet made a significant contribution to the management of these patients. Unlike the three types of peptides, anti-platelet factor IV, DMP 444 and snake venom factors, being investigated as agents to detect PE and DVT, the peptide in question CSVTCG, is the one that exists naturally in the molecular domain of the most endogenous protein, thrombospondin, which takes an active part in the formation of DVT via activated platelets. Also, unlike the other three peptides, CSVTCG binds to major platelets glycoprotein CD 36 (GPIV, GPV). "We have successfully labeled CSVTCG with Tc-99m, examined its biological activity and determined its ability to selectively bind to activated platelets via GP CD 36. We have evaluated Tc-99m-CSVTCG (Tc-99m-TP-1201) to label forming and preformed blood clots in vitro and to detect an experimental DVT in vivo. The results have been highly encouraging and have generated the impetus that has prompted us to undertake this systematic feasibility study that will determine its potential as an agent for scintigraphic imaging of DVT and PE." PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE